Endothelial-Specific Targeting of RhoA Signaling via CD31 Antibody-Conjugated Nanoparticles.

Area of Science:

• Biomedical Engineering
• Molecular Biology
• Pharmacology

Background:

• Vascular endothelial growth factor (VEGF)-targeted antiangiogenic therapies can cause significant side effects.
• The RhoA signaling pathway in endothelial cells plays a crucial role in angiogenesis.
• Fasudil is a clinically relevant inhibitor of Rho-associated kinase (ROCK), a key effector of RhoA.

Purpose of the Study:

• To develop a novel antiangiogenic strategy by targeting endothelial RhoA signaling.
• To create Fasudil-encapsulated liposomes that specifically target CD31 on endothelial cells.
• To evaluate the efficacy of these targeted liposomes in inhibiting angiogenesis.

Main Methods:

• Generation of Fasudil-encapsulated liposomes conjugated with CD31-targeting antibodies.
• Assessment of liposome binding specificity to CD31-expressing cells and endothelial cells.
• Evaluation of Fasudil's effect on endothelial cell stress fiber formation, cytoskeletal morphology, and in vitro angiogenic functions.

Main Results:

• The CD31-targeting liposomes demonstrated preferential binding to target cells.
• Liposome treatment inhibited stress fiber formation and altered endothelial cell morphology.
• In vitro assays confirmed the inhibition of angiogenic functions by the targeted Fasudil delivery.

Conclusions:

• Nanodelivery-mediated targeting of endothelial RhoA signaling via Fasudil-loaded liposomes is a viable antiangiogenic strategy.
• This approach shows potential for reducing systemic toxicity associated with conventional antiangiogenic therapies.
• The study validates the benefits of site-targeted antiangiogenic therapy for vascular-related diseases.